Drug intelligence / Profile preview

Kaitong Buzu Re granules

Development stage: Unknown
Lead developer: Xinjiang Uygur Autonomous Region Institute of Drug Research
Administration: Oral

Overview

Kaitong Buzu Re granules is a traditional Chinese medicine (TCM) developed by the Xinjiang Uygur Autonomous Region Institute of Drug Research. It is formulated as granules for oral administration and is primarily indicated for the treatment of acute hepatitis A, specifically targeting the liver–gallbladder damp-heat syndrome according to TCM diagnostic criteria. The drug has been evaluated in a randomized, double-blind, placebo-controlled Phase II clinical trial in China to assess its efficacy and safety in adult patients with acute hepatitis A.

Other names: Kaitong Buzu Re Granules

Beyond the preview

Go deeper on Kaitong Buzu Re granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kaitong Buzu Re granules.

Explore the full profile